DOCSLIB.ORG

ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2015 (Advance Copy)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2015 (Advance Copy) ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2015 (Advance Copy) Total of estimates before adjustment to stocks Afghanistan* Ethylmorphine 10 Codeine 37 500 Etorphine 10 Dextropropoxyphene 1 500 000 Heroin 100 Diphenoxylate 15 000 Hydrocodone 10 Fentanyl 5 Hydromorphone 1 500 Methadone 4 500 Ketobemidone 10 Morphine 3 000 Levorphanol 10 Pethidine 60 000 Methadone 40 000 Pholcodine 75 000 Morphine 350 Albania Normethadone 10 Codeine 25 500 Normorphine 10 Fentanyl 6 Opium 10 Methadone 13 000 Oripavine 10 Morphine 4 500 Oxycodone 17 000 Pethidine 2 500 Oxymorphone 300 Pholcodine 1 100 Pethidine 29 000 Remifentanil 8 Phenoperidine 10 Sufentanil 1 Pholcodine 10 Algeria Piritramide 10 Alfentanil 350 Remifentanil 2 120 Codeine 1 000 000 Sufentanil 10 Etorphine 1 Thebacon 10 Fentanyl 500 Thebaine 22 000 Morphine 9 000 Tilidine 10 Pethidine 3 000 Armenia Pholcodine 1 500 000 Codeine 3 000 Remifentanil 1 Fentanyl 30 Sufentanil 30 Methadone 10 000 Andorra Morphine 5 000 Cannabis 1 500 Thebaine 12 Fentanyl 80 Trimeperidine 1 000 Methadone 1 000 Aruba* Morphine 500 Alfentanil 3 Oxycodone 1 500 Bezitramide 1 Pethidine 500 Cocaine 70 Remifentanil 4 Codeine 85 Angola* Dextromoramide 1 Alfentanil 2 Dextropropoxyphene 85 Codeine 22 500 Fentanyl 130 Dextromoramide 375 Hydrocodone 2 Dihydrocodeine 375 Methadone 150 Fentanyl 45 Morphine 440 Morphine 11 000 Opium 450 Pethidine 14 000 Oxycodone 26 Sufentanil 2 Pethidine 404 Anguilla Piritramide 50 Codeine 500 Remifentanil 19 Fentanyl 1 Ascension Island Morphine 20 Alfentanil 1 Pethidine 300 Fentanyl 1 Antigua and Barbuda* Morphine 1 Cocaine 9 Pethidine 5 Codeine 169 Australia Dihydrocodeine 15 Alfentanil 650 Diphenoxylate 28 beta-Hydroxyfentanyl 1 Fentanyl 1 Cannabis 10 000 Morphine 6 Cocaine 12 000 Oxycodone 2 Codeine 6 210 000 Pethidine 338 Conc. of poppy straw Remifentanil 1 ACA 4 000 Sufentanil 1 AMA 29 591 400 Argentina AOA 4 000 Alfentanil 10 ATA 12 305 040 Alphaprodine 10 Dextromoramide 8 Anileridine 10 Dextropropoxyphene 350 000 Bezitramide 10 Dihydrocodeine 75 000 Cannabis 50 Diphenoxylate 50 000 Cannabis resin 20 Etorphine 2 Coca leaf 250 Fentanyl 45 000 Cocaine 120 Heroin 1 Codeine 25 000 Hydrocodone 25 Dextromoramide 10 Hydromorphone 85 000 Dextropropoxyphene 1 100 000 Methadone 1 100 000 Difenoxin 10 Morphine 800 000 Dihydrocodeine 10 Opium 1 Diphenoxylate 10 Oxycodone 2 200 000 Dipipanone 10 Oxymorphone 2 000 - 1 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2015 (Advance Copy) Total of estimates before adjustment to stocks Pethidine 80 000 Methadone 15 000 Pholcodine 700 000 Morphine 100 000 Remifentanil 600 Oxymorphone 25 000 Sufentanil 4 Pethidine 395 000 Thebaine 1 000 Barbados Austria Cocaine 245 Alfentanil 450 Codeine 85 000 Cannabis 50 000 Dihydrocodeine 900 Cocaine 2 200 Fentanyl 25 Codeine 500 000 Heroin 1 Codeine-N-oxide 50 Hydromorphone 3 Dextropropoxyphene 100 Methadone 248 Dihydrocodeine 650 000 Morphine 4 422 Diphenoxylate 40 Pethidine 8 060 Ethylmorphine 100 Remifentanil 125 Etorphine 5 Sufentanil 1 Fentanyl 50 000 Belarus Heroin 5 Alphaprodine 1 Hydrocodone 10 Cocaine 100 Hydromorphone 150 000 Codeine 3 000 000 Methadone 110 000 Dextromoramide 1 Morphine 2 200 000 Dextropropoxyphene 1 000 Morphine-N-oxide 15 Dipipanone 1 Nicomorphine 2 000 Ecgonine 1 Opium 13 000 Ethylmorphine 100 Oripavine 100 Etorphine 1 Oxycodone 320 000 Fentanyl 2 000 Oxymorphone 100 Heroin 1 Pethidine 20 000 Hydromorphone 2 500 Piritramide 22 000 Methadone 38 000 Remifentanil 4 500 Morphine 14 000 Sufentanil 600 Norcodeine 1 Thebaine 110 Normorphine 1 Tilidine 100 Oxycodone 1 Azerbaijan Oxymorphone 1 Codeine 2 000 Pethidine 1 Fentanyl 25 Remifentanil 1 Methadone 6 000 Sufentanil 2 Morphine 800 Thebaine 1 Trimeperidine 1 800 Trimeperidine 50 000 Bahamas Belgium 6-Acetylmorphine 1 Acetyldihydrocodeine 20 Alfentanil 1 Alfentanil 43 000 Cannabis 4 Cannabis 20 000 Cannabis resin 4 Cocaine 12 000 Cocaine 4 Codeine 3 875 000 Codeine 2 000 Codeine-N-oxide 1 Desomorphine 1 Conc. of poppy straw Dextropropoxyphene 2 800 AMA 604 500 Dihydrocodeine 1 Dextromoramide 20 Dihydromorphine 1 Dextropropoxyphene 1 000 Ecgonine 1 Dihydrocodeine 500 Fentanyl 300 Diphenoxylate 100 Heroin 1 Ecgonine 1 Hydrocodone 1 Ethylmorphine 210 000 Hydromorphone 150 Etorphine 5 Methadone 1 Fentanyl 766 000 Morphine 1 000 Heroin 1 500 Opium 4 Hydrocodone 500 Oxycodone 1 300 Hydromorphone 20 000 Oxymorphone 1 Levorphanol 10 Pethidine 10 000 Methadone 350 000 Sufentanil 2 Morphine 125 000 Thebaine 1 Nicomorphine 10 Tilidine 1 Opium 25 000 Bahrain Oripavine 100 Alfentanil 1 Oxycodone 210 000 Codeine 6 000 Oxymorphone 20 Etorphine 3 Pethidine 40 000 Fentanyl 100 Phenoperidine 50 Methadone 100 Pholcodine 80 000 Morphine 2 000 Piritramide 20 000 Oxycodone 300 Remifentanil 30 000 Pethidine 10 000 Sufentanil 1 200 Remifentanil 150 Thebacon 10 Bangladesh Thebaine 100 Fentanyl 800 Tilidine 2 115 000 - 2 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2015 (Advance Copy) Total of estimates before adjustment to stocks Belize Fentanyl 7 Cocaine 100 Morphine 10 000 Codeine 10 000 Oxycodone 410 Dextropropoxyphene 4 000 Pethidine 20 000 Dihydrocodeine 50 Sufentanil 3 Diphenoxylate 50 Tilidine 300 Fentanyl 4 Brazil Hydrocodone 100 Alfentanil 2 179 Hydromorphone 100 Alphaprodine 1 Methadone 1 000 Anileridine 1 Morphine 4 000 Bezitramide 1 Oxycodone 250 Cocaine 2 Pethidine 4 200 Codeine 1 731 039 Benin Codeine-N-oxide 1 Codeine 2 000 Dextromoramide 1 Fentanyl 500 Dextropropoxyphene 1 001 Morphine 1 000 Difenoxin 1 Pethidine 5 000 Dihydrocodeine 1 Remifentanil 10 Diphenoxylate 1 000 Sufentanil 1 Dipipanone 1 Bermuda* Ethylmorphine 1 Alfentanil 8 Etorphine 1 Cannabis 2 Fentanyl 1 653 Cannabis resin 1 Heroin 1 Cocaine 113 Hydrocodone 1 Codeine 3 750 Hydromorphone 15 847 Dextromoramide 11 Ketobemidone 1 Dextropropoxyphene 1 Levorphanol 1 Dihydrocodeine 1 500 Methadone 62 346 Diphenoxylate 113 Morphine 2 279 800 Dipipanone 1 Nicomorphine 1 Etorphine 4 Normethadone 1 Fentanyl 45 Opium 227 500 Heroin 1 Oripavine 1 Hydrocodone 11 Oxycodone 69 850 Hydromorphone 113 Oxymorphone 1 Methadone 3 000 Pethidine 312 258 Morphine 1 125 Phenoperidine 1 Oxycodone 450 Pholcodine 1 Oxymorphone 1 Piritramide 1 Pethidine 2 250 Remifentanil 3 286 Pholcodine 75 Sufentanil 10 Remifentanil 15 Thebacon 1 Bhutan Thebaine 1 Codeine 800 Tilidine 1 Fentanyl 2 British Virgin Islands Morphine 120 Codeine 104 Pethidine 1 300 Dihydrocodeine 90 Bolivia (Plurinational State of) Diphenoxylate 15 Codeine 347 800 Fentanyl 10 Dextropropoxyphene 450 000 Morphine 130 Fentanyl 121 Oxycodone 200 Methadone 900 Pethidine 800 Morphine 5 710 Brunei Darussalam Oxycodone 11 521 Alfentanil 2 Pethidine 16 530 Codeine 5 000 Remifentanil 384 Dihydrocodeine 1 000 Bosnia and Herzegovina Fentanyl 28 Alfentanil 30 Heroin 1 Cannabis 2 Morphine 1 500 Cannabis Oil 1 Pethidine 1 300 Cannabis resin 2 Pholcodine 1 000 Cocaine 1 Remifentanil 3 Codeine 1 196 Bulgaria Fentanyl 1 095 Alfentanil 30 Heroin 1 Cannabis 6 500 Methadone 24 793 Cocaine 1 Morphine 6 287 Codeine 3 000 000 Pethidine 550 Codeine-N-oxide 2 Pholcodine 21 388 Dextromoramide 1 Remifentanil 30 Dextropropoxyphene 500 Sufentanil 5 Dihydrocodeine 30 000 Botswana Ecgonine 2 Alfentanil 9 Ethylmorphine 10 000 Codeine 18 000 Fentanyl 500 Dihydrocodeine 1 000 Heroin 1 Etorphine 20 Hydromorphone 1 - 3 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2015 (Advance Copy) Total of estimates before adjustment to stocks Isomethadone 5 Sufentanil 200 Methadone 150 000 Thebaine 100 Morphine 70 000 Tilidine 1 Morphine-N-oxide 2 Cayman Islands* Normorphine 1 Alfentanil 1 Opium 10 Cannabis 2 Oxycodone 30 000 Cocaine 15 Oxymorphone 1 Codeine 23 Pethidine 25 000 Dihydrocodeine 38 Piritramide 1 000 Fentanyl 23 Remifentanil 25 Heroin 20 Sufentanil 20 Hydrocodone 188 Tilidine 40 000 Hydromorphone 53 Burkina Faso* Methadone 30 Fentanyl 3 Morphine 300 Morphine 14 000 Oxycodone 600 Pethidine 18 000 Oxymorphone 113 Remifentanil 1 Pethidine 1 050 Sufentanil 1 Central African Republic* Burundi Codeine 15 000 Codeine 1 400 Fentanyl 3 Fentanyl 130 Methadone 1 500 Morphine 1 200 Morphine 6 000 Pethidine 4 000 Pethidine 4 000 Cabo Verde Chad Alfentanil 1 Fentanyl 1 Cannabis 2 Morphine 47 Cannabis resin 1 Pethidine 150 Cocaine 1 Chile Codeine 40 Alfentanil 12 Fentanyl 8 Cannabis 5 Heroin 1 Cocaine 40 Methadone 8 Codeine 888 000 Morphine 250 Ethylmorphine 4 500 Pethidine 250 Fentanyl 4 500 Cambodia Methadone 17 340 Codeine 305 000 Morphine 160 000 Dextropropoxyphene 515 000 Morphine-N-oxide 3 Fentanyl 50 Oxycodone 8 200 Methadone 15 000 Pethidine 35 000 Morphine 15 000 Remifentanil 400 Oxycodone 100 Sufentanil 1 Pethidine 500 China Cameroon* Alfentanil 5 Codeine 20 000 Cannabis 5 Fentanyl 8 Cocaine 5 000 Morphine 11 000 Codeine 10 350 000 Pethidine 11 000 Conc. of poppy straw Canada AMA 25 030 000 Alfentanil 300 ATA 270 000 Alphaprodine 1 Dihydrocodeine 850 000 Anileridine 1 Diphenoxylate 2 820 000 Cannabis 55 546 440 Etorphine 50 Cocaine 20 000 Fentanyl 38 000 Codeine 30 392 500 Hydrocodone 20 000 Dextromoramide 1 Hydromorphone 5 000 Dextropropoxyphene 500 Methadone 4 200 000 Dihydrocodeine 50 Morphine 10 900 000 Diphenoxylate 50 000 Opium 12 600 000 Ethylmorphine 2 Oxycodone 900 000 Etorphine 2 Pethidine 2 500 000 Fentanyl 150 000 Pholcodine 610 000 Heroin 17 325 Remifentanil 20 000 Hydrocodone 100 000 Sufentanil 8 000 Hydromorphone 1 500 000 Thebaine 650 000 Ketobemidone 1 Tilidine 30 000 Levorphanol 100 Hong Kong Special Administrative Region of Methadone 2 500 000 China Morphine 4 000 000 Alfentanil 20 Normethadone 20 000
Load more

Recommended publications
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Emerging Drug Trends 2014
    EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center Emerging Drug Trends Table of Contents Opioid Abuse .................................................... 2 By ROCIC Publications Specialist Jennifer Adkins Opiate Abuse .................................................... 7 © Regional Organized Crime Information Center Synthetic Cathinones ..................................... 13 ew drugs are emerging at an unprecedented rate as manufacturers Synthetic Cannabinoids ................................. 18 of “legal high” products use new chemicals to replace those that Phenethlyamines ............................................ 22 N Party Pills ...................................................27 are banned. These new chemicals take the place of heroin, morphine, and amphetamines. These drugs are highly accessible, touted as legal, Herbal Drugs ..............................................29 Sources of Information ...............................32 and perceived as safe. This Special Research Report was supported by Grant No. 2011-RS-CX-K007, awarded by the Bureau of Justice Assistance, Office of Justice Programs, U.S. However, despite the popularity in designer drugs and legal high Department of Justice. The Office of Justice Programs also coordinates the activi- ties of the Bureau of Justice Statistics, the National Institute of Justice, the Office of products, the abuse of heroin and prescription painkiller medication Juvenile Justice and Delinquency, and the Office for Victims of Crime.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • Medication Assisted Treatment Guidelines for Opioid Use Disorders
    STATE OF MICHIGAN Medication Assisted Treatment Guidelines for Opioid Use Disorders MAT Work Group R. Corey Waller MD, MS 9/17/2014 This document was developed to be a consolidated, short form set of updated, evidence-based guidelines for the treatment of opioid use disorders. Prior to starting the manuscript, current relevant guidelines were reviewed. These included, but were not limited to, the World Health Organization Guidelines, the Baltimore Buprenorphine guidelines, the Vermont Buprenorphine Guidelines, the Australian Ministry of Health Methadone Guidelines as well as the Canadian Department of Health Guidelines for use of Methadone and Buprenorphine. All National Institutes of Drug Addiction (NIDA) as well as SAMHSA materials were used in the initial review. Once this was done all information was updated to current as of April 2014. R. Corey Waller MD, MS was the primary author with Shelly Virva LMSW having authored most of the General Behavioral Health Section. The material was then reviewed by the Medication Assisted Treatment workgroup as directed by Lisa Miller (Michigan Department of Community Health) and suggested changes were incorporated. This document was not meant to be an exhaustive philosophical or theoretical journey about treatment beliefs, but rather a consolidation of current evidence that can guide the treatment, safety, efficacy and payment models driving the treatment of opioid use disorders moving forward. SECTION PG 01 Introduction ..................................................................................................................................................................................................................................
    [Show full text]
  • Dimeric Alkaloids from Tasmanian-Grown Papaver
    Substances naturelles d'origine végétale 151 DIMERIC ALKALOmS FROM TASMANIAN·GROWN PAPAVER SOMNIFERUM Charles DRAGAR and 1. Ralph C. BICK· Agricultural Science Department. • Chemistry Department. University ofTasmania. Hobart. Tasmania. Australia 7005. Apart from wide-spread illicit cultivation, the opium poppy (Papaver somniferum) is grown under official control for preparing ethical drugs in various countries extending from the Balkans through to India. Disorders in much of this region have led 10 Tasmania being chosen 10 provide a stable supply, and in consequence a special poppy variety was developed which would give good yields of alkaloid under local conditions. However, while a high content of morphine has been achieved, considerable variation in the nature and content ofthe minor bases has ensued. Many varieties of P. somniferum exist, with divergent morphological characteristics and alkaloidal constituents. Different countries have selected those varieties best adapted 10 local conditions, with the result that opium from different sources varies considerably in composition. The tirst four entries in Table 1 relate to varieties cultivated in the main countries where it is legally grown (1 ,2, 3). These are followed by figures for varieties grown illicitly in two other countries (4). Table 1: Principal Opium Alkaloids from Poppy Varieties grown in ditTerent Countries (%) (1, 2,3,4) Morphine Narcotine Codeine Papaverine Thebaine Thrkey 10-16 3-4 0.3-1.4 1-1.5 1-1.5 Yugoslavia 13-17 2-9 0.3-1.5 1-1.5 0.8-1.2 Iran 9-12 5-6 2.5-4 2-2.5 3-4 India 10-11 6-9 2.5-4 0.8 0.5-1 Thailand 7-18 3-10 2-5 0.3 2-6 Mexico 3-17 5-17 1-4 2-8 0.2-1.9 Altogether about sixtY alkaloids have been isolated from different varieties of poppy (5), reflecting the large amount of work carried out on this plant As far as Tasmanian-grown poppies are concemed, narcotine, a major constituent of Indian opium in particular, is virtually absent, but much higher amounts of thebaine are present than in other opiums.
    [Show full text]
  • Narcotic Drugs — Estimated World Requirements for 2018
    English — Comments COMMENTS ON THE REPORTED STATISTICS ON NARCOTIC DRUGS Part two Part Summary The further overall reduction in global stocks and in the production of opium confirm the con- Deuxi tinuing trend towards the eventual elimination of the drug from the international market for è opiate raw material. me partie Poppy straw and concentrate of poppy straw derived from the two main varieties of poppy straw (the morphine-rich and thebaine-rich varieties) decreased slightly in 2016 compared Segunda parte with 2015, and the manufacture of morphine remained stable at 422.1 tons, of which around 87 per cent of global manufacture was converted into other narcotic drugs or into substances not covered by the 1961 Convention. Of the remaining 13 per cent, only 8.6 per cent was directly consumed for palliative purposes. The differences in consumption levels between countries continued to be very significant. In 2016, 80 per cent of the world population consumed only 14 per cent of the total amount of morphine used for the management of pain and suffering. Although that represented an improvement on 2014, when 80 per cent of the world population consumed 9.5 per cent, the disparity in consumption of narcotic drugs for palliative care continues to be a matter of concern. After some fluctuations in the preceding years, global manufacture of thebaine reached the record level of 156 tons in 2016, signalling that the demand for medicines derived from thebaine, after having decreased in the past several years, appears to have resumed, despite restrictions on prescription drugs recently imposed in the main market (the United States of America) in response to their abuse and the high number of overdose deaths they have caused.
    [Show full text]
  • EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center
    EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center Emerging Drug Trends Table of Contents Opioid Abuse .................................................... 2 By ROCIC Publications Specialist Jennifer Adkins Opiate Abuse .................................................... 7 © Regional Organized Crime Information Center Synthetic Cathinones ..................................... 13 ew drugs are emerging at an unprecedented rate as manufacturers Synthetic Cannabinoids ................................. 18 of “legal high” products use new chemicals to replace those that Phenethlyamines ............................................ 22 N Party Pills ...................................................27 are banned. These new chemicals take the place of heroin, morphine, and amphetamines. These drugs are highly accessible, touted as legal, Herbal Drugs ..............................................29 Sources of Information ...............................32 and perceived as safe. This Special Research Report was supported by Grant No. 2011-RS-CX-K007, awarded by the Bureau of Justice Assistance, Office of Justice Programs, U.S. However, despite the popularity in designer drugs and legal high Department of Justice. The Office of Justice Programs also coordinates the activi- ties of the Bureau of Justice Statistics, the National Institute of Justice, the Office of products, the abuse of heroin and prescription painkiller medication Juvenile Justice and Delinquency, and the Office for Victims of Crime.
    [Show full text]
  • Structural and Pharmacological Properties of Alkaloids with Special Reference to Thebaine Type Alkaloids
    Research Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2019.17.002993 Structural and Pharmacological Properties of Alkaloids with Special Reference to Thebaine Type Alkaloids Tugba Taskin Tok1 and Sivakumar JT Gowder2 ,3* 1Department of Chemistry, Gaziantep University, 27310, Gaziantep, Turkey 2Department for Management of Science and Technology Development, Ton Duc Thang University, Vietnam 3Faculty of Applied Sciences, Ton Duc Thang University, Vietnam *Corresponding author: Sivakumar JT Gowder, Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Faculty of Applied Sciences, Vietnam, email: ARTICLE INFO abstract Received: April 10, 2019 Alkaloids are pharmacologically active compounds and have a wide array of ther Published: April 24, 2019 apeutic value. Though they exhibit medicinal properties, we need to evaluate the ad verse effects of alkaloids though their structural pharmacological properties. By using a- - Citation: Tugba T T, Sivakumar J G. Structural and Pharmacological includeDiels-Alder heteroaromatic reaction (D-A), rings. we Gaussian09 identified novel and DiscoveryD-A adducts, Studio obtained 3.5 softwares with thebaine were perand Properties of Alkaloids with Special formedvarious fromdienophiles, basic to benzylidene advance basis malononitrile sets for these (1-28) compounds and metilen by using malononitrile quantum chemical (29-38) Reference to Thebaine Type Alka - 2019. BJSTR. MS.ID.002993. - descriptors such as electrophilicity index, (ω), global hardness (η) and electronic charge loids. Biomed J Sci & Tech Res 17(3)- (ΔN) to predict the probable chemical and biochemical activities of thebaine derivatives. Keywords: Alkaloids; Cytotoxicity; The endo forms of 2-(4-nitrobenzylidene)malononitrile, (o-4 and p-5) display significant- Abbreviations: ly high tendency in the electrophilicity index (ω) and electronic charge (ΔN) values.
    [Show full text]
  • Oripavine (Final Decision)
    34th ECDD - 2006/6.3 oripavine (final decision) Oripavine (final decision) a. Introduction Oripavine, O3-demethylthebaine, is a phenanthrene alkaloid contained in various species of the genus Papaver, including P. bracteatum Lindl. and P. orientale L.. It is not produced by traditionally cultivated varieties of opium poppy (P. somniferum L.) and is therefore not found in opium. However, in the last decade, a variety (a strain) of P. somniferum was created by plant breeders with a high content of oripavine and is now cultivated commercially on a considerable scale. Oripavine was pre-reviewed by the 33rd ECDD in 2002. The reason for pre-review in 2002 was that oripavine is a substance that is convertible into thebaine, and because thebaine in its turn is convertible into morphine. Thebaine and morphine are both in Schedule I of the 1961 Convention, morphine because of its liability for abuse, and thebaine because it can be converted into substances that are morphine derivatives and are included in Schedule I of the 1961 Convention because of their liability for abuse. The Committee concluded from this that the conversion of oripavine into morphine derivatives was indirect and therefore it hesitated whether Article 3, para. 3 point iii of the 1961 Convention was applicable in this case. The Committee also remarked that the relation of this situation to the 1988 Convention is not clear, as the latter regulates substances frequently used in the production of narcotic drugs or psychotropic substances. Due to these uncertainties, the 33rd ECDD did not finalize this review, but included in its report the following proposal: "The Committee urged WHO to develop additional scheduling guidelines in consultation with appropriate bodies of the United Nations for clarifying issues related to the conversion of precursors into scheduled substances." However, supplementary Guidelines for the WHO review of dependence producing psychoactive substances for international control have not been established by WHO Executive Board, as will be discussed in a separate point on the agenda.
    [Show full text]